Adapalene (1-200 μM; 24 h) inhibits the viability of ES-2, HOV-7, MCF-7 , Hela, SW1990, HT1080, and MM-468 cells, with IC50s of 10.36 μM, 10.81 μM, 12.00 μM, 19.08 μM, 19.52 μM, 21.70 μM, and 31.47 μM, respectively.
Adapalene (10-40 μM; 24 h) induces ES-2 cells apoptosis and inhibits proliferation in vitro.
Adapalene (3-30 μM; 6-24 h) significantly increases the G1-phase population in LoVo or DLD1 cells.
Adapalene (1-200 μM) inhibits GOT1 activity, with an IC50 of 21.79 μM.
Adapalene (10-10 nM) inhibits the expression of plasma membrane-associated enzyme transglutaminase Type I, with an IC50 of 2.5 nM.
Cell Viability Assay
Cell Line: |
Pancreatic cancer (SW1990, Aspc-1), breast cancer (mm-231, mm-468, MCF-7), liver cancer (Hep3B), cervical cancer (Hela), ovarian cancer (HOV-7, ES-2), normal cells (CHO, L929) |
Concentration: |
1-200 μM |
Incubation Time: |
24 hours |
Result: |
Inhibited the viability of cancer cells with higher GOT1 protein expression. |
Apoptosis Analysis
Cell Line: |
ES-2 cells |
Concentration: |
10, 20, 40 μM |
Incubation Time: |
24 hours |
Result: |
Showed a significant increase in apoptosis compared with the control group.
Down regulated the expression of anti-apoptotic protein Bcl-2 and PARP.
|
Cell Cycle Analysis
Cell Line: |
LoVo or DLD1 cells |
Concentration: |
3, 10, 30 μM |
Incubation Time: |
6, 12, 24 hours |
Result: |
Caused cell cycle arrest in G1 phase in a dose- and time-dependent manner.
|